AbbVie’s (ABBV) Dividend Track Record: A Testament to Stability

Core Insights - AbbVie Inc. is recognized as one of the 12 Best Dividend Aristocrat Stocks to invest in currently [1] - The company operates in a highly defensive biopharmaceutical industry, characterized by stable demand for its innovative medicines [2] - AbbVie has a diversified portfolio across various therapeutic areas, including immunology, oncology, neuroscience, and eye care [2] Financial Performance - AbbVie has maintained a strong revenue and earnings stream due to its focus on treating serious or chronic diseases, which supports its dividend program [3] - The company has consistently increased its dividends for 53 consecutive years, currently offering a quarterly dividend of $1.64 per share, yielding 2.98% as of September 26 [4] Strategic Developments - AbbVie is expanding into the obesity market through a partnership with Gubra A/S, involving an initial investment of $350 million, with potential total payments reaching $2.25 billion based on clinical milestones and future royalties [3]